473 related articles for article (PubMed ID: 29159826)
21. Comparative targeting analysis of KLF1, BCL11A, and HBG1/2 in CD34
Lamsfus-Calle A; Daniel-Moreno A; Antony JS; Epting T; Heumos L; Baskaran P; Admard J; Casadei N; Latifi N; Siegmund DM; Kormann MSD; Handgretinger R; Mezger M
Sci Rep; 2020 Jun; 10(1):10133. PubMed ID: 32576837
[TBL] [Abstract][Full Text] [Related]
22. Genetic association studies in β-hemoglobinopathies.
Thein SL
Hematology Am Soc Hematol Educ Program; 2013; 2013():354-61. PubMed ID: 24319204
[TBL] [Abstract][Full Text] [Related]
23. Genomic approaches to identifying targets for treating β hemoglobinopathies.
Ngo DA; Steinberg MH
BMC Med Genomics; 2015 Jul; 8():44. PubMed ID: 26215470
[TBL] [Abstract][Full Text] [Related]
24. Therapeutic hemoglobin levels after gene transfer in β-thalassemia mice and in hematopoietic cells of β-thalassemia and sickle cells disease patients.
Breda L; Casu C; Gardenghi S; Bianchi N; Cartegni L; Narla M; Yazdanbakhsh K; Musso M; Manwani D; Little J; Gardner LB; Kleinert DA; Prus E; Fibach E; Grady RW; Giardina PJ; Gambari R; Rivella S
PLoS One; 2012; 7(3):e32345. PubMed ID: 22479321
[TBL] [Abstract][Full Text] [Related]
25. Genome editing using CRISPR-Cas9 to create the HPFH genotype in HSPCs: An approach for treating sickle cell disease and β-thalassemia.
Ye L; Wang J; Tan Y; Beyer AI; Xie F; Muench MO; Kan YW
Proc Natl Acad Sci U S A; 2016 Sep; 113(38):10661-5. PubMed ID: 27601644
[TBL] [Abstract][Full Text] [Related]
26. Discovering the genetics underlying foetal haemoglobin production in adults.
Thein SL; Menzel S
Br J Haematol; 2009 May; 145(4):455-67. PubMed ID: 19344402
[TBL] [Abstract][Full Text] [Related]
27. Genome editing approaches to β-hemoglobinopathies.
Brusson M; Miccio A
Prog Mol Biol Transl Sci; 2021; 182():153-183. PubMed ID: 34175041
[TBL] [Abstract][Full Text] [Related]
28. Recent Progress in Gene Therapy and Other Targeted Therapeutic Approaches for Beta Thalassemia.
Hamed EM; Meabed MH; Aly UF; Hussein RRS
Curr Drug Targets; 2019; 20(16):1603-1623. PubMed ID: 31362654
[TBL] [Abstract][Full Text] [Related]
29. The switch from fetal to adult hemoglobin.
Sankaran VG; Orkin SH
Cold Spring Harb Perspect Med; 2013 Jan; 3(1):a011643. PubMed ID: 23209159
[TBL] [Abstract][Full Text] [Related]
30. Identifying genetic variants and pathways associated with extreme levels of fetal hemoglobin in sickle cell disease in Tanzania.
Nkya S; Mwita L; Mgaya J; Kumburu H; van Zwetselaar M; Menzel S; Mazandu GK; Sangeda R; Chimusa E; Makani J
BMC Med Genet; 2020 Jun; 21(1):125. PubMed ID: 32503527
[TBL] [Abstract][Full Text] [Related]
31. Heterogeneity of fetal hemoglobin production in adult red blood cells.
Khandros E; Blobel GA
Curr Opin Hematol; 2021 May; 28(3):164-170. PubMed ID: 33631783
[TBL] [Abstract][Full Text] [Related]
32. Molecular basis of β thalassemia and potential therapeutic targets.
Thein SL
Blood Cells Mol Dis; 2018 May; 70():54-65. PubMed ID: 28651846
[TBL] [Abstract][Full Text] [Related]
33. Emerging Genetic Therapy for Sickle Cell Disease.
Orkin SH; Bauer DE
Annu Rev Med; 2019 Jan; 70():257-271. PubMed ID: 30355263
[TBL] [Abstract][Full Text] [Related]
34. Editing a γ-globin repressor binding site restores fetal hemoglobin synthesis and corrects the sickle cell disease phenotype.
Weber L; Frati G; Felix T; Hardouin G; Casini A; Wollenschlaeger C; Meneghini V; Masson C; De Cian A; Chalumeau A; Mavilio F; Amendola M; Andre-Schmutz I; Cereseto A; El Nemer W; Concordet JP; Giovannangeli C; Cavazzana M; Miccio A
Sci Adv; 2020 Feb; 6(7):. PubMed ID: 32917636
[TBL] [Abstract][Full Text] [Related]
35. Gene editing for sickle cell disease and transfusion dependent thalassemias- A cure within reach.
Eckrich MJ; Frangoul H
Semin Hematol; 2023 Jan; 60(1):3-9. PubMed ID: 37080708
[TBL] [Abstract][Full Text] [Related]
36. Enhanced HbF reactivation by multiplex mutagenesis of thalassemic CD34+ cells in vitro and in vivo.
Psatha N; Georgakopoulou A; Li C; Nandakumar V; Georgolopoulos G; Acosta R; Paschoudi K; Nelson J; Chee D; Athanasiadou A; Kouvatsi A; Funnell APW; Lieber A; Yannaki E; Papayannopoulou T
Blood; 2021 Oct; 138(17):1540-1553. PubMed ID: 34086867
[TBL] [Abstract][Full Text] [Related]
37. Future prospects for treatment of hemoglobinopathies.
Stamatoyannopoulos JA
West J Med; 1992 Dec; 157(6):631-6. PubMed ID: 1282285
[TBL] [Abstract][Full Text] [Related]
38. Fetal Hemoglobin Regulation in Beta-Thalassemia.
Lu HY; Orkin SH; Sankaran VG
Hematol Oncol Clin North Am; 2023 Apr; 37(2):301-312. PubMed ID: 36907604
[TBL] [Abstract][Full Text] [Related]
39. Clinical variability and molecular characterization of Hbs/Gγ (Aγδβ)0-thal and Hbs/HPFH in Indian sickle cell disease patients: AIIMS experience.
Pandey H; Singh K; Ranjan R; Pandey SK; Sharma A; Kishor K; Seth T; Mahapatra M; Saxena R
Hematology; 2019 Dec; 24(1):349-352. PubMed ID: 30777489
[TBL] [Abstract][Full Text] [Related]
40. Molecular genetics of β-thalassemia: A narrative review.
Jaing TH; Chang TY; Chen SH; Lin CW; Wen YC; Chiu CC
Medicine (Baltimore); 2021 Nov; 100(45):e27522. PubMed ID: 34766559
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
